articleThe Lancet NeurologyJun 3, 2011Closed access

Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2)

St. Michael's Hospital · University of Toronto · +10 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

635
total citations
FWCI
32.92
Percentile
100%
References
31
Citations per year

Authors

13

Topics & keywords

Keywords
  • Endothelin receptor antagonist
  • Medicine
  • Glasgow Outcome Scale
  • Subarachnoid hemorrhage
  • Placebo
  • Endovascular coiling
  • Clinical endpoint
  • Vasospasm
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding